Showa Denko

SDK Formulates 'Long-term Vision (2021-2030) for Newly Integrated Company'

Retrieved on: 
Thursday, December 10, 2020
Fuyo Group, Showa Denko, Intel, Economy of Japan, Companies

(SDK; TSE:4004) has formulated its future "Long-term Vision (2021-2030) for Newly Integrated Company" (Long-term Vision) following integration with Showa Denko Materials Co., Ltd. (Showa Denko Materials).

Key Points: 
  • (SDK; TSE:4004) has formulated its future "Long-term Vision (2021-2030) for Newly Integrated Company" (Long-term Vision) following integration with Showa Denko Materials Co., Ltd. (Showa Denko Materials).
  • In terms of purpose, the Newly Integrated Company will seek to "change society through the power of chemistry."
  • The Group will pursue business development with a good understanding of differences in market stages and our position in each business.
  • (SDK; TSE:4004, ADR:SHWDY) is a major manufacturer of chemical products serving from heavy industry to computers and electronics.

Showa Denko Subsidiary Establishes Branch in Xi'an, China to Distribute High-purity Gases for Electronics

Retrieved on: 
Wednesday, December 9, 2020
Cities in China, Sub-provincial cities in the People's Republic of China, Fuyo Group, Showa Denko, Geography of China, Industrial gases, Precious metals, Nines, Shaanxi, Wuhan, Xi'an, Shanghai

TOKYO, Dec 9, 2020 - (JCN Newswire) - Shanghai Showa Chemicals Co., Ltd. (SSC), a Chinese subsidiary of Showa Denko K.K.

Key Points: 
  • TOKYO, Dec 9, 2020 - (JCN Newswire) - Shanghai Showa Chemicals Co., Ltd. (SSC), a Chinese subsidiary of Showa Denko K.K.
  • (SDK; TSE:4004), established a branch in Xi'an, Shaanxi Province, China, and started operation of the branch in December 2020, aiming to strengthen its business to sell and distribute high-purity gases for electronics in China.
  • The new branch is SSC's third business base in China to sell and distribute high-purity gases for electronics, following those in Shanghai and Wuhan.
  • And we will expand our business to produce and sell high-purity gases for electronics by responding positively to the lasting vigorous demand for high-purity gases.

Showa Denko Announces Changes in Corporate Management

Retrieved on: 
Monday, November 30, 2020
Showa Denko, Economy of Japan, Companies

TOKYO, Nov 30, 2020 - (JCN Newswire) - Showa Denko (SDK; TSE:4004) decided at its Board of Directors meeting today on changes in corporate management (directors, corporate officers and councilors).

Key Points: 
  • TOKYO, Nov 30, 2020 - (JCN Newswire) - Showa Denko (SDK; TSE:4004) decided at its Board of Directors meeting today on changes in corporate management (directors, corporate officers and councilors).
  • Hisashi Maruyama (President and CEO, Showa Denko Materials Co., Ltd.) will be elected Director of SDK at the General Meeting of Shareholders in late March 2021.
  • Meanwhile, Katsuyuki Tsuji (Associate Councilor; General Manager, Advanced Battery Materials Division; President, Showa Denko Packaging Co., Ltd.) will be newly appointed Corporate Officer on January 4.
  • Showa Denko K.K., CSR & Corporate Communication Office, Tel: 81-3-5470-3235
    Copyright 2020 JCN Newswire .

Showa Denko Establishes Joint Corporation in Sichuan, China to Manufacture High-purity Gas for Electronics

Retrieved on: 
Friday, November 6, 2020
Chemical compounds, Cities in China, Chengdu, Carbon tetrafluoride, Chemistry, Showa Denko

(SDK; TSE:4004) has established Chengdu Kemeite Showa Electronic Materials Co., Ltd. in Chengdu, China, jointly with Chengdu Kemeite Special Gas Co., Ltd. of China, aiming to strengthen SDK's business to produce and sell high-purity gases for electronics.

Key Points: 
  • (SDK; TSE:4004) has established Chengdu Kemeite Showa Electronic Materials Co., Ltd. in Chengdu, China, jointly with Chengdu Kemeite Special Gas Co., Ltd. of China, aiming to strengthen SDK's business to produce and sell high-purity gases for electronics.
  • Exterior view of the building of Chengdu Kemeite Special Gas Co., Ltd. where the new company will move in
    CF4 is one of major products of SDK's electronic gas business.
  • CF4 is the primary and basic etching gas among high-purity gases for electronics, and has been mass-produced and used for more than 40 years.
  • (40%); Chengdu Kemeite Special Gas Co., Ltd. (60%)
    [Outline of Chengdu Kemeite Special Gas Co., Ltd.]
    Firm name: Chengdu Kemeite Special Gas Co., Ltd.

Showa Denko Announces 2020 Third Quarter Financial Results

Retrieved on: 
Thursday, November 5, 2020
Fuyo Group, Showa Denko, Economy of Japan, Companies, Intel

TOKYO, Nov 5, 2020 - (JCN Newswire) - Showa Denko K.K.

Key Points: 
  • TOKYO, Nov 5, 2020 - (JCN Newswire) - Showa Denko K.K.
  • (SDK; TSE:4004) today announced its 2020 third quarter financial results.
  • Showa Denko K.K.
  • (SDK; TSE:4004, ADR:SHWDY) is a major manufacturer of chemical products serving from heavy industry to computers and electronics.

DGAP-News: Minaris Regenerative Medicine GmbH: Minaris Regenerative Medicine to Significantly Expand Manufacturing Capacity for Cell and Gene Therapies in Germany and Japan

Retrieved on: 
Monday, November 2, 2020
Branches of biology, Life sciences, Biology, Regenerative biomedicine, Fuyo Group, Showa Denko, Regenerative medicine, Contract manufacturing organization

MUNICH, Germany and YOKOHAMA, Japan - Nov. 2, 2020 - Minaris Regenerative Medicine ("Minaris"), a leading global contract development and manufacturing organization for cell and gene therapies, wholly owned by Showa Denko Materials Co., Ltd., announced today a total investment of 64.5 million USD to significantly expand its facilities in Europe and Asia.

Key Points: 
  • MUNICH, Germany and YOKOHAMA, Japan - Nov. 2, 2020 - Minaris Regenerative Medicine ("Minaris"), a leading global contract development and manufacturing organization for cell and gene therapies, wholly owned by Showa Denko Materials Co., Ltd., announced today a total investment of 64.5 million USD to significantly expand its facilities in Europe and Asia.
  • The new facility will operate according to GMP standards (FDA and EMA) and be dedicated to clinical and commercial manufacturing as well as development services for cell and gene therapies.
  • A new facility will also be established adjacent to the existing facility in Yokohama, Japan allowing for an additional 4,000 sqm which will double the capacity for commercial manufacturing of regenerative medicine.
  • Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies.

SDK to Split Its Optical Semiconductor Business

Retrieved on: 
Tuesday, October 27, 2020
Fuyo Group, Showa Denko, Economy of Japan, Companies

TOKYO, Oct 27, 2020 - (JCN Newswire) - Showa Denko (SDK; TSE:4004) decided at its Board of Directors' meeting today to split its business in optical semiconductors and rare earth alloys through an absorption-type company split effective January 1, 2021 (hereinafter "the Company Split").

Key Points: 
  • TOKYO, Oct 27, 2020 - (JCN Newswire) - Showa Denko (SDK; TSE:4004) decided at its Board of Directors' meeting today to split its business in optical semiconductors and rare earth alloys through an absorption-type company split effective January 1, 2021 (hereinafter "the Company Split").
  • As the Company Split is to be implemented through a simplified absorption-type company split between SDK and its wholly-owned subsidiary, part of details is omitted in this disclosure.
  • The optical semiconductor business is classified as one of the "Grow" businesses under the plan.
  • This will be an absorption-type company split, with SDK serving as the splitting company and Showa Denko Photonics as the succeeding company.

Showa Denko Announces Merger between Consolidated Subsidiaries and Change of Company Name

Retrieved on: 
Thursday, September 24, 2020
Fuyo Group, Showa Denko, SDCH, Economy of Japan, Shōwa, Companies

TOKYO, Sept 24, 2020 - (JCN Newswire) - Showa Denko (SDK; TSE:4004) decided at its Board of Directors meeting held today that its consolidated subsidiary Showa Denko Carbon Holding GmbH (SDCH) will merge with its consolidated subsidiary Showa Denko Europe GmbH (SDE), and that the surviving company SDCH will change its company name into Showa Denko Europe GmbH (new SDE) effective as of January 1, 2021.

Key Points: 
  • TOKYO, Sept 24, 2020 - (JCN Newswire) - Showa Denko (SDK; TSE:4004) decided at its Board of Directors meeting held today that its consolidated subsidiary Showa Denko Carbon Holding GmbH (SDCH) will merge with its consolidated subsidiary Showa Denko Europe GmbH (SDE), and that the surviving company SDCH will change its company name into Showa Denko Europe GmbH (new SDE) effective as of January 1, 2021.
  • However, in order to clarify its business management function in Europe, SDCH will change its company name into "Showa Denko Europe GmbH" at the same date of the merger.
  • SDCH will change its company name into "Showa Denko Europe GmbH" at the same date.
  • Since this is a case of merger between wholly owned subsidiaries, SDK's consolidated performance will not be affected materially by the merger.

DGAP-News: Hitachi Chemical Co., Ltd.: Hitachi Chemical's Global Regenerative Medicine Business Renamed Minaris Regenerative Medicine

Retrieved on: 
Wednesday, September 23, 2020
Companies, Articles, Economy of Japan, Fuyo Group, Tissue engineering, Hitachi, Regenerative medicine, Regenerative medicine, Showa Denko, Regenerative design

The regenerative medicine business of Hitachi Chemical Co., Ltd. ("Hitachi Chemical") announces that, effective today, it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry.

Key Points: 
  • The regenerative medicine business of Hitachi Chemical Co., Ltd. ("Hitachi Chemical") announces that, effective today, it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry.
  • "By working and using the single name Minaris Regenerative Medicine, we will strengthen our brand perception and recognition as a unified, global CDMO, intensify our cooperation with and further expand our integrated services for our clients," said Kazuchika Furuishi, PhD, Corporate Officer and General Manager, Regenerative Medicine Business Sector of Hitachi Chemical and CEO of Minaris Regenerative Medicine, LLC.
  • The wholly-owned regional subsidiary companies and entities within Minaris Regenerative Medicine, encompassing a global footprint of over 200,000 square feet and employee base of over 500, have adopted the same name:
    - North America: Hitachi Chemical Advanced Therapeutics Solutions, LLC is renamed Minaris Regenerative Medicine, LLC, effective today
    - Europe: apceth Biopharma GmbH is renamed Minaris Regenerative Medicine GmbH, effective today
    Hitachi Chemical, the parent company of Minaris Regenerative Medicine, will be renamed Showa Denko Materials, Co., Ltd. on October 1, 2020 as previously announced.
  • Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies.

Showa Denko Joins 'The Valuable 500'

Retrieved on: 
Tuesday, September 8, 2020
Fuyo Group, Showa Denko, Economy of Japan, Companies

The Valuable 500 was launched at the World Economic Forum Annual Meeting in Davos held in January 2019.

Key Points: 
  • The Valuable 500 was launched at the World Economic Forum Annual Meeting in Davos held in January 2019.
  • In addition, with this signing as motivation, the Showa Denko Group will start an in-house campaign named "Uniqueness Supporter 500."
  • Diversity and inclusion activities of the Showa Denko Group: https://www.sdk.co.jp/csr/Labor_Practices/employee.html
    Showa Denko K.K.
  • Showa Denko K.K., CSR & Corporate Communication Office, Tel: 81-3-5470-3235
    Copyright 2020 JCN Newswire .